Exposure assessment is an integral part of health risk characterization. Exposure assessments typically address three critical aspects of exposure: the number of people exposed to the environmental toxicant, at specific concentrations, for the time period of interest; the resulting dose; and the relative contribution of important sources and pathways to exposure/dose. Because historically both "point-of-contact" measurements and information about dose and related pharmacokinetic processes have been lacking, exposure assessments have had to rely on construction of "scenarios" to estimate exposure and dose. This could change, however, as advances in development of biologic markers of exposure and dose make it possible to measure and interpret toxicant concentrations in accessible human tissues. The increasing availability of "biomarkers," coupled with improvements in pharmacokinetic understanding, present opportunities to estimate ("reconstruct") exposure from measurements of dose and knowledge of intake and uptake parameters. Human tissue monitoring, however, is not a substitute for more traditional methods of measuring exposure, but rather a complementary approach. A combination of exposure measurements and dose measurements provides the most credible scientific basis for exposure assessment. -Environ Health Perspect (Suppl 3): 13-30 (1995) 
Introduction
People are exposed to a variety of environmental agents, including biologic, chemical, and physical entities, in the air they breathe, the water they drink, the food they eat, the surfaces they contact, and the products they use. Sometimes, exposures to environmental toxicants are sufficient to cause adverse health consequences, such as birth defects, cancer, neurobehavioral effects, and respiratory disease. The quantitative estimation of such health risks, based on information about exposure and dose-response relationships, is fundamental to policy decisions about which risks are unacceptable and how best to manage them (1) (2) (3) (4) (5) .
Establishing a causal relationship between exposures and subsequent disease This paper was presented at the Conference on Human Tissue Monitoring and Specimen Banking: Opportunities for Exposure Assessment, Risk or injury is usually difficult unless the link is very strong, as with radon-induced lung cancer in uranium miners. The difficulties arise because environmentally induced chronic disease is highly complex: multiple exposures and causative agents, long latency periods, and variability within and among individuals must be considered. The lack of appropriate data on human exposures, doses, and related effects contribute further to the difficulties encountered by risk assessors. In general, attempts to quantify health risks resulting from exposures to environmental agents are hindered by one or both of two pervasive problems: 1) appropriate and adequate scientific data are not available; and 2) available data are difficult or impossible to interpret because we do not have adequate scientific understanding (6) .
Realistic risk assessment depends on accurate estimation of both exposures and toxicity related to health effects. Most of the research emphasis historically has been on reducing uncertainties associated with health effects (e.g., inherent toxicity, dose-response relationship). Experience has shown, however, that lack of exposure data and a defiency of understanding about important exposure mechanisms are major sources of scientific uncertainty in most risk assessments (2) (3) (4) (5) (7) (8) (9) (10) (11) (12) (13) (14) .
Human exposure analysis is currently recognized as an important topic of scientific investigation, one that is complementary to more traditional public health disciplines, such as epidemiology and toxicology. The need for exposure-related research is brought home by the paucity of empirical information available to estimate exposures, and associated doses, for most environmental agents deemed to have public health significance. The data on hand tend to be anectodal, fragmented, uneven, and narrowly focused on single pathways and routes of exposure for individual chemicals (2) (3) (4) (5) 10, 11, (15) (16) (17) (18) (19) (20) . The purpose of this article is to explain how exposure assessments are conducted in the context of risk characterization, with particular emphasis on the importance of establishing the link between exposure and associated dose. We begin with a brief overview of the major uses of exposure information. We next focus specifically on the importance of exposure evaluation for realistic assessment of environmental health risks, and look conceptually at how individuals and groups who are potentially at greater risk are identified. We summarize the key concepts and definitions germane to exposure estimation, examine the basic components of exposure assessment, and compare three approaches to quantitative exposure estimation. The final section provides a short discussion of the growing importance of human for realistic assessment of exposures to environmental agents.
Uses of Human Exposure Information
There are four interrelated uses of human exposure data for evaluation and protection of environmental health: risk assessment, effects assessment (i.e., hazard identification, dose-response evaluation) are integral parts of this process. The goal is to use the best available information and knowledge to estimate health risks for the subject population, important subgroups within the population (e.g., children, pregnant women, and the elderly), and individuals at the center and "high end" of the exposure distribution (1, 10, 11, 21) . The results of risk assessment feed directly into the risk management process carried out by policymakers. Risk management decisions are of four basic types: priority setting, determination of unacceptable risks, selection of the most cost-effective method to prevent or reduce unacceptable risks, and evaluation of the success of risk mitigation efforts. Exposure information is crucial to each of these decisions. In addition to data on exposures and related health effects, decisionmakers also must take account of the economic, engineering, legal, social, and political aspects of the problem (11, 15) .
Evaluation of current status and historical trends for exposures and doses is an important component of both risk assessment and risk management. It requires collecting exposure data over a relatively long period (e.g., 5 to 10 years), which assures that temporal trends can be identified and understood. Data on status and trends can be invaluable for identifying new or emerging problems, recognizing the relative importance of emission sources and exposure pathways, assessing the effectiveness of pollution controls, distinguishing opportunities for epidemiologic research, and predicting future changes in exposures and effects (11, 16) .
Epidemiology is the study of the determinants and distribution of health status (or health-related events) in human populations. Environmental epidemiology examines associations between exposures to environmental agents and associated disease or injury. It is a scientific tool that can sometimes detect environmentally induced health effects in populations, and it may offer opportunities to link actual exposures with adverse health outcomes (11, 17) Well-designed epidemiologic studies can provide unique and powerful information that is directly relevant to risk assessment and to risk management decisions. In addition to their other uses, these studies can characterize the health status of populations, describe disease occurrence through identification of explanatory factors, and evaluate efforts at disease prevention and reduction.
Environmental Health Perspectives
But without reliable exposure information, epidemiologic studies are much less useful for decision making. The excess risk for most environmentally related health effects is small, with relative risks and odds ratios typically less than 2. Failure to correctly classify or quantify exposures can introduce misclassification error that may artificially reduce the level of risk observed and thus limit the usefulness of the study (11, 17) .
In addition to these four uses of human exposure information, such data also may be essential for recognizing, diagnosing, and treating environmentally induced illness, such as lead poisoning. Although exposure assessments are undertaken for a variety of reasons, the subsequent discussion focuses on their use for characterizing environmental health risks.
Exposure Assessment as a Critical Factor in Risk Characterization
Actions taken by society to protect its members from the harmful consequences of environmental agents are predicated on established or postulated links among emission sources, human exposures, and adverse health effects. The chain of events depicted in Figure 2 is an "environmental health paradigm": a simplified representation of the key steps between emission of toxic agents into the environment and potential disease or dysfunction in humans. This sequential series of events serves as a useful construct to aid in understanding and evaluating environmental health risks (6, 11, 22) .
Estimation of health risks associated with environmental agents is composed of two primary activities: exposure assessment and effects assessment (Figure 2 ). Exposure assessment focuses on the initial portion of the environmental health paradigm: from sources, to environmental concentrations, to exposure, to dose. The major goal is to develop a qualitative and quantitative description of the environmental agent's contact with (exposure) and entry into (dose) the human body. Much emphasis is placed on estimating the magnitude, duration, and frequency of exposures, as well as estimating the number of people exposed to various concentrations of the agent in question. Ideally, the relative contribution of all important sources and pathways is determined at the same time (1) (2) (3) (4) (5) 21, 23) .
Effects assessment (Figure 2 ) examines the latter portion of the events continuum: from exposure, to dose, to adverse health effects. The goals are to determine the Figure 3 . Basic elements in the estimation and prioritization of environmental health risks (24) .
intrinsic hazards associated with the agent (hazard identification) and to quantify the relationship between dose to the target tissue and related harmful outcomes (doseresponse assessment). The overlap between exposure assessment and effects assessment reflects the importance of the exposure-dose relationship to both activities (11) . Risk characterization is the last phase of the risk assessment process. The results of the exposure and the effects assessments are combined to estimate the human health risks from the anticipated exposures. For example, a typical cancer risk characterization would estimate both the magnitude (e.g., 20 excess cancer cases yearly in the United States population) and the likelihood (e.g., maximally exposed person in the population runs a risk of 1 in 1,000,000 for developing cancer) of risks from exposures to an environmental carcinogen.
Conceptually, as shown in Figure 3 , estimating and prioritizating health risks are deceptively simple. Risk is a combination of effects estimates and exposure estimates, where "highest" priority risks can be thought of as those that entail both "high" toxicity for the agent of interest (adverse effects are likely to occur in humans at relatively low exposures or doses), and "high" exposures for the population, subpopulation, or individuals of interest (exposures or doses are above a health-based standard). Conversely, "lowest" priority risks involve both "low" toxicity and "low" exposures. "Medium" priority risks are those for which either toxicity or exposure is "low" while the other is "high" (24) . In practice, a variety of methods and approaches can be used to estimate both toxicity and exposure ( Figure 3 ). Estimates are more realistic the closer the surrogate is to the event of interest (e.g., exposure), and the more accurate the model is for extrapolating to individuals for whom measurements are unavailable (5, 11 Figure 5A ). In most cases, however, the shape of the doseresponse curve above the benchmark is poorly defined, making it difficult or impossible to estimate risks quantitatively (6, (26) (27) (28) (29) .
Quantitative risk assessment for carcinogens is a well-established (30,31) albeit controversial procedure. As part of the guidelines developed by the U.S. EPA, it is common practice to extrapolate from high to low dose by assuming a linear, nonthreshold model for carcinogenicity. Under this assumption, cancer risk for individuals can be estimated directly from the exposure or dose distribution, and the number of excess cancer cases (i.e., the increase above background rates) in the exposed population can usually be estimated by multiplying the average dose by both the total number of people exposed and the dose-response slope factor ( Figure 5B ). Although individual risk is assumed to increase with increasing exposure and dose all along the distribution, exposures of concern are typically defined to be those above some de minimis level of risk (e.g., a 1 in 1,000,000 excess risk of developing cancer). Individuals and groups can also be at increased risk because they are more susceptible to the adverse effects of a given exposure. Among the potential causes of enhanced susceptibility are: inherent genetic variability, age, gender, preexisting disease (e.g., diabetes, asthma), inadequate diet, lifestyle factors (e.g., smoking), stress, and inadequate access to health care. To the extent feasible, it is important to identify these susceptible individuals and groups so that we can understand their exposures and take account of this information in assessing and managing risks (1, 21 Figure 2 is depicted in Figure 8 . It shows the domain of exposure assessment, which includes important events, mechanisms, and processes that provide a context for understanding and estimating exposures and doses for environmental agents.
The release of an agent into the environment, its ensuing transport, transformation, and fate in various environmental media, and its ultimate contact with people are critical events in understanding 19 - as the "intake rate," which is the product of the exposure concentration times the rate of either ingestion or inhalation. Uptake. Uptake is associated with the dermal route of exposure, as well as with ingestion and inhalation after intake has occurred. The agent, as with intake, is likely to be part of a carrier medium (e.g., water, soil, consumer product), but enters the body by crossing an absorption barrier, such as the skin, respiratory tract, or gastrointestinal tract. The rates of bulk transport across the absorption barriers are generally not the same for the agent and the carrier medium. The amount of the agent that crosses the barrier per unit time can be referred to as the "uptake rate". This rate is a function of the exposure concentration, as well as of the permeability and surface area of the exposed barrier. The uptake rate is also called a "flux".
Dose. Once the agent enters the body by either intake or uptake, it is described as a "dose." Several different types of dose are relevant to exposure estimation.
Potential (Administered) Dose. Potential, or administered dose, is the amount of the agent that is actually ingested, inhaled, or applied to the skin. The concept of potential dose is straightforward for inhalation and ingestion, where it is analogous to the dose administered in a dose-response experiment. For the dermal route, however, it is important to keep in mind that potential (or administered) dose refers to the amount of the agent, whether in pure form or as part of a carrier medium, that is applied to the surface of the skin. In cases where the agent is in diluted form as part of a carrier medium, not all of the potential dose will actually be touching the skin.
Applied Dose. Applied dose is the amount of the agent directly in contact with the body's absorption barriers, such as the skin, respiratory tract, and gastrointestinal tract, and therefore available for absorption. Information is rarely available on applied dose, so it is calculated from potential dose based on factors such as bioavailability ( Figure 6 ).
Internal (Absorbed) Dose. The amount of the agent absorbed, and therefore available to undergo metabolism, transport, storage, or elimination, is referred to as the "internal" or "absorbed dose" (Figure 6 ).
Delivered Dose (Body Burden). The portion of the internal (absorbed) dose that reaches a tissue of interest is called the "delivered dose."
Biologically Effective (Target) Dose. The portion of the delivered dose that reaches the site or sites of toxic action is called the "biologically effective dose."
The link, if any, between biologically effective dose and subsequent disease or illness depends on the relationship between dose and response (e.g., shape of the dose-response curve), underlying pharmacodynamic mechanisms (e.g., compensation, damage, repair), and important susceptibility factors (e.g., health status, nutrition, stress, genetic predisposition).
Biologic Effect. A measurable response to dose in a molecule, cell, or tissue is termed a "biologic effect." The significance of a biologic effect, whether it is an indicator or a precursor for subsequent adverse health effects, may not be known.
Adverse Effect. A biologic effect that causes dysfunction, injury, illness, or death is defined as an "adverse health effect."
Linking Exposure Events and Dose Events The schematic framework in Figure 9 shows how the interrelationships among significant exposure-and dose-related events in the paradigm can be conceived. The example assumes that perfect information on exposure and dose is available for a hypothetical population exposed to a single agent by multiple pathways and routes. To make realistic estimates for a specific event (e.g., an internal dose), it is necessary to have at least one of two types of information: measurements of the event itself (e.g., internal dose); or measurements of an earlier (e.g., potential dose) or later (e.g., delivered dose) event in the continuum. It is also necessary to understand the critical intervening mechanisms and processes (e.g., pharmacokinetics) that govern the relationship between the event measured and the event of interest (e.g., internal dose). Unless such data are on hand, extrapolating from one event to another, moving from either exposure to dose (from left to right in Figure 9 ) or from dose to exposure (from right to left in Figure 9 ), is problematic. functional form of models, misuse of proxy data from analogous contexts. The first step in any exposure assessment must be to determine which data are necessary; the next step must be to specify how to obtain them. These steps can be accomplished by addressing a series of questions about the assessment's purpose, scope, level of detail, and approach (21, 23 application of this approach depends on the availability of measurements of biomarkers in human tissue so that internal dose can be realistically reconstructed (calculated), and adequate information to accurately estimate intake, uptake, and metabolic rates. Examples of the types of biomarkers measured in human tissue that can be used for reconstructing internal dose and their relevance to exposure assessment are given in Table 3 .
The strength of the reconstructive approach is that it can demonstrate unequivocally that exposure and uptake have occurred. However, because internal dose is integrated across all routes of exposure, the method does not usually provide information about the relative importance of inhalation, ingestion, and dermal absorption. Perhaps the most serious problem with implementing this approach is 
Role of Human Tissue Monitoring in Exposure Assessment
The vast majority of quantitative risk assessments conducted by the U.S. EPA have dealt with lifetime cancer risks from long-term exposures to low levels of single chemicals via one pathway or route. In the face of a serious lack of data on both cancer potency and lifetime exposures in humans, an elaborate set of guidelines has been developed for cancer risk assessment (30, 31) . The guidelines provide assessors with formal guidance on how and when to apply a variety of "default" assumptions to estimate carcinogenic risk. For example, in the absence of evidence to the contrary, it is common to assume that a high dose of a carcinogen received over a short time is equivalent to a corresponding low dose spread over a lifetime.
Most cancer risk assessments have been done by constructing scenarios because there is an absence of adequate and appropriate data; because there is a lack of scientific understanding to interpret available data. Of necessity, these scenarios have incorporated default assumptions to estimate exposure and dose. The scenario approach is based on a logical, stepwise analysis of the important events in the environmental health paradigm (Figures 8,9 ), from source, through pathways, to exposure, and ultimately to biologically effective dose. Important parameters (e.g., emission rates, product-use patterns, transport and fate processes, concentrations in food and water, human consumption patterns, uptake rates, metabolism, are either estimated from available data or assumed to be represented adequately by default values.
Because information is lacking, scenarios do not usually include a complete description of the exposure and dose distribution for the population of interest. Instead, scenarios emphasize estimating several points on the population distribution of lifetime individual exposures (or doses) (Figures 4,5B) . Historically, three of these points have been: average exposure (dose), which is related to the total number of excess cancer cases expected in the population from the anticipated exposures; exposure (dose) for an individual in the upper tail of the distribution; and exposure (dose) for the most exposed individual in the distribution. Although scenarios have obvious limitations, such as lack of data, unvalidated default assumptions, and point estimates of exposure or dose, that contribute significantly to uncertainties in risk assessment, they remain the only viable method to estimate exposure or dose in the absence of direct measurements.
Historically, human tissue measurements have played a relatively small role in most exposure assessments because of the nature of the risks being assessed (e.g., lifetime cancer risk related to "average" lifetime exposure or dose), the types of questions being asked (e.g., what incremental risks are associated with a single source/pathway/route), the lack of appropriate human tissue data (e.g., no data for the population/situation of interest), and our still largely deficient understanding of pharmacokinetics (e.g., we cannot yet interpret human tissue measurements in terms of exposure).
Biologic Markers (Biomarkers) of Exposure
Many of the dose-related and healthrelated events in the environmental health (45) .
comparing exposure indices (e.g., a combination of environmental measurements and questionnaire data) with measurements of delivered dose (body burden). As shown in Table 6 , they found that there was no correlation in three of the five cases. They concluded that when indirect measures, such as questionnaires, concentrations in environmental media, and proximity to sources, are used to estimate or classify exposures, it is important to "validate and calibrate" the exposure index against direct measurements of "internal dose" in at least a subset of the potentially exposed population. Wallace pg/dl to 10 pg/dl (47) .
The decision to phase out lead in gasoline presents a dramatic illustration of the value of blood lead as a biomarker of exposure. Prior to the decision, exposure models suggested that eliminating lead in gasoline would have a slight effect on blood lead levels (47) . However, as shown in Figure 11 , data from the second National Health and Nutrition Examination Survey (NHANES II) revealed that as lead in gasoline decreased (about 55%) from 1976 to 1980 when unleaded fuel was introduced, there was a parallel decrease (about 37%) in mean blood lead levels in the United States population (from approximately 16 pg/dl to less than 10 pg/dl) (47, 48 (52, 53) , and a broad spectrum of the scientific community (10, 11, (15) (16) (17) The NRC goes on to say, "All these characteristics, taken together, make tissue monitoring as an assessment tool an important adjunct to environmental monitoring that is uniquely valuable in indicating both exposures and doses that lead to potentially harmful effects" (4).
Changes in Nature and Scope of Risk Assessments
There are indications that the nature and scope of risk assessments are expanding in important ways, which may have significant ramifications for the role of human tissue monitoring in exposure assessment. Risks other than cancer, including adverse effects on reproduction, development, the nervous system, pulmonary and cardiovascular function, and the immune system, are becoming more important in regulatory and policy decisions. In addition to lifetime exposures, concerns increasingly focus on a wide variety of shorter term exposures: exposures from accidental or emergency releases of hazardous materials (hours or days); peak air pollution exposures during stagnant meteorological conditions (hours or days); peak waterborne exposures caused by runoff from agricultural activities (hours or days); exposures to pregnant women and fetuses during critical developmental periods (minutes or hours); and exposures of "sensitive" individuals (e.g., allergic, hypersensitive) to brief contact with environmental agents (minutes, hours, or days).
The scope of risk assessment is also broadening from a narrow focus on incremental risks associated with individual environmental agents and single exposure pathways. Now the emphasis is often on understanding "total" exposure for an individual or population from all important sources, pathways, and routes of exposure, either for a specific agent or mixture of agents. For example, instead of looking only at incremental risks related to air pollution emissions from a particular source, assessors are beginning to examine comparative and cumulative risks for the population of a defined geographic area from all important sources, via all important pathways.
These and related changes in risk assessment are being driven by a move toward more comprehensive management of environmental health risks. The magnitude and extent of environmental health problems, the associated costs of mitigation and remediation, and the need to balance the nation's budget are forcing hard societal decisions about strategic directions and how resources will be allocated among competing needs. A broad-based consensus seems to be emerging that "risk-based priority setting" is the method of choice to ensure that scarce resources are used to address the "worst" problems first. In essence, risk-based priority setting compares and ranks health risks (both cancer and noncancer), as well as other types of risks (e.g., welfare, ecologic), to establish priorities for resource allocation (24) .
This "comparative" risk approach focuses attention on the components of "total" environmental health risk for people in a defined geographic area, such as a metropolitian center, state, region, or the entire country. To achieve its goal of identifying the worst comparative risks, riskbased priority setting requires data or informed estimates of total exposures for the population of interest. Thus, it creates an immediate need for exposure assessments that are qualitatively different from those traditionally conducted.
In the context of total exposure assessments, scenario construction alone becomes a less viable option because of the difficulties in identifying, let alone quantifying the relative contributions of all important exposure pathways. Further 
Summary and Conclusions
Realistic assessment of health risks associated with exposures to environmental agents depends on adequate knowledge and understanding of both exposures and their associated effects. Within the risk assessment framework, exposure assessment is a formalized process, subject to explicit guidelines, that attempts to estimate the number of people exposed to specific concentrations of the agent for the period of interest, the resulting dose, and the contribution of important sources and pathways to exposure and dose. Because direct measurements of exposure and dose are scarce, and because of the narrow focus of the questions being asked, most assessments historically have been conducted by constructing exposure scenarios.
Theoretically, concentrations of environmental agents or their metabolites/ derivatives measured in human tissues and excreta can be used to "reconstruct" internal dose. If this information is then combined with intake and uptake rates, it is possible to calculate associated exposures. In practice, "reconstructive exposure assessment" is seldom used because we lack appropriate pharmacokinetic information to link biomarker measurements to exposure. However, continuing scientific and technological advances in the measurement and understanding of biomarkers, as well as changes in the nature and scope of risk assessments, indicate that this approach has significant potential to improve the realism of exposure assessments.
It is important to remember, however, that direct measurements of exposure and measurements of dose are not substitutes for each other. They are complementary rather than competing methods for conducting realistic exposure assessments. The most scientifically credible risk characterizations will employ a combination of both types of evidence. Ultimately, whether measurements of biomarkers strengthen, and perhaps "revolutionize," exposure assessments depends on the extent to which we achieve a better understanding of the interrelationships among exposure pathways, exposure concentrations, and related dose.
